AstraZeneca’s Zomig patents upheld in precedential ruling
02-07-2018
Rawpixel.com / Shutterstock.com
The Patent Trial and Appeal Board (PTAB) has rejected generics company Lannett Holdings’s petition for an inter partes review (IPR) because it was filed one day too late.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB; USPTO; AstraZeneca; Lannett Holdings; IPR; Impax Laboratories; US District Court for the District of Delaware; Zomig